Genscript Biotech (HKEX: 01548) opened nearly 15% higher in Hong Kong trading.

At the time of writing, the stock was up 14.99% to HK$13.96, with a turnover of HK$6.17 million.

The catalyst for the surge was a more than 42% jump in the share price of its US-listed affiliate, Legend Biotech (NASDAQ: LEGN), overnight, which pushed its market capitalisation to approximately US$6.7 billion.

Key Development

Genscript Biotech announced that Legend Biotech has disclosed preliminary clinical data for its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, LB2501, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

The company stated that the preliminary clinical data has shown positive signals.

This data is scheduled to be presented in the Late-Breaking Abstracts session at the 2026 European Hematology Association (EHA) Annual Congress, which will be held in Stockholm, Sweden, from June 11 to June 14, 2026.

Management Commentary

Dr. Ying Huang, CEO of Legend Biotech, commented that the upcoming Phase 1 data for LB2501 demonstrates significant progress in the in vivo CAR-T strategy for B-cell malignancies.

By generating CAR-T cells directly within the patient's body, this approach has the potential to simplify the treatment process and improve accessibility for patients who are difficult to reach with conventional CAR-T cell therapies.

Technology Platform

LB2501 is developed based on the TaVec™ platform, a proprietary lentiviral vector designed to enhance T-cell targeting specificity, transduction efficiency, and safety, while limiting transduction of non-T cells.